Cervical Screening & Benign Cervical Lesions

Cervical cancer is almost entirely preventable because it has a long, screenable pre-invasive phase. This topic ties together the anatomy of the transformation zone, the Pap smear (cytology), the Bethesda reporting system, colposcopy-directed biopsy (histology), and the treatment of CIN — plus the common benign lesions that mimic disease. NEET PG loves single-best-answer questions on "next step" for a given Bethesda result.

---

1. Relevant anatomy — the battleground

The cervix is lined by two different epithelia, and the cancer arises precisely where they meet.

Feature	Ectocervix	Endocervix
Epithelium	Stratified squamous (non-keratinised)	Simple columnar (mucus-secreting)
Appearance	Smooth, pink	Reddish, velvety, glandular
Glycogen	Present (stains brown with Lugol's)	Absent

Squamocolumnar junction (SCJ): the line where squamous meets columnar epithelium.

Transformation zone (TZ): the region between the original SCJ and the new SCJ, where columnar epithelium has undergone squamous metaplasia. This is the site of origin of >90% of cervical cancers and the target of every screening and treatment manoeuvre.

High-yield: The transformation zone is where almost all cervical neoplasia begins. Both Pap sampling and colposcopic biopsy must capture the TZ to be adequate.

Position of the SCJ shifts with hormonal status:

• Puberty/pregnancy/OCP use (high oestrogen) → SCJ moves out onto the ectocervix → columnar epithelium becomes visible as ectropion/ectopy.
• Menopause → SCJ recedes into the endocervical canal → TZ may be unseen on colposcopy → makes colposcopy "unsatisfactory/inadequate" in older women.

---

2. Benign cervical lesions (the mimics)

Lesion	Key points
Cervical ectropion (ectopy/erosion)	Eversion of endocervical columnar epithelium onto ectocervix; physiological in adolescents, pregnancy, OCP users. Red, granular, bleeds on contact. Usually asymptomatic — treat only if symptomatic (discharge, post-coital bleeding) with cautery/cryo after excluding malignancy.
Nabothian cyst (Nabothian follicle)	Retention mucous cyst from squamous metaplasia blocking an endocervical gland. Benign, no treatment needed.
Cervical (endocervical) polyp	Most common benign cervical neoplasm; bright red, pedunculated; causes intermenstrual/post-coital bleeding. Avulse/twist off and send for histology (rule out malignancy).
Cervical fibroid	May cause dystocia/obstruction.
Cervicitis	Infective (Chlamydia, Gonorrhoea, Trichomonas) — mucopurulent discharge, friable cervix.

High-yield: A cervical polyp is twisted off at its base and always sent for histopathology; an asymptomatic ectropion needs no treatment, only reassurance after excluding malignancy.

---

3. Aetiology & pathophysiology of cervical neoplasia

Human papillomavirus (HPV) is the necessary cause.

• High-risk (oncogenic) types: 16 and 18 → cause ~70% of cervical cancers. (Also 31, 33, 45, 52, 58.)
• Low-risk types 6 and 11 → genital warts (condyloma acuminata), not cancer.

Mechanism: Oncoproteins E6 (inactivates p53) and E7 (inactivates Rb) drive uncontrolled proliferation. Most HPV infections clear spontaneously; persistent infection with a high-risk type is what progresses to CIN and cancer.

Risk factors: early age at first intercourse, multiple sexual partners, high parity, smoking, immunosuppression (HIV), long-term OCP use, low socioeconomic status, co-infection (HSV, Chlamydia).

Disease continuum: Normal → HPV infection → CIN 1 (LSIL) → CIN 2/3 (HSIL) → invasive carcinoma. This evolution takes 10–20 years, which is exactly why screening works.

---

4. Cervical Intraepithelial Neoplasia (CIN) — histological grading

CIN is a histological diagnosis (from biopsy), graded by how much of the epithelial thickness is replaced by dysplastic cells:

CIN grade	Epithelial involvement	Old dysplasia term	Two-tier (LAST/WHO)
CIN 1	Lower 1/3	Mild dysplasia	LSIL
CIN 2	Lower 2/3	Moderate dysplasia	HSIL
CIN 3	Full thickness (not through basement membrane)	Severe dysplasia / CIS	HSIL

Once dysplastic cells breach the basement membrane, it becomes invasive carcinoma.

High-yield: CIN = histology (biopsy). SIL/Bethesda = cytology (Pap). Do not confuse the two terminologies — exams test this distinction directly.

---

5. The Pap smear (cervical cytology)

A screening test, not diagnostic. It samples exfoliated cells from the TZ.

Technique essentials:

• Best timed in the mid-cycle, avoid menses.
• Avoid douching/intercourse/vaginal medication for 48 h prior.
• Insert speculum without lubricant (saline only).
• Ayre's spatula samples the ectocervix; endocervical brush (cytobrush) samples the canal — together they ensure TZ sampling.
• Conventional Pap: smear on slide, fix immediately in 95% ethyl alcohol (avoid air-drying artefact).
• Liquid-based cytology (LBC): cells suspended in fixative — fewer unsatisfactory smears, allows reflex HPV testing; now preferred.

Stain used: Papanicolaou stain.

High-yield: Speculum is inserted without lubricant; conventional smears are fixed immediately in 95% ethanol. LBC permits reflex HPV testing from the same vial.

Limitations: sensitivity of a single Pap is only ~50–60% for high-grade lesions (improved by repeat testing); adenocarcinoma (endocervical) is under-detected.

---

6. The Bethesda System (2014) — Pap reporting

This is the most heavily tested sub-topic. Bethesda reports cytology, classifying squamous abnormalities:

Bethesda category	Meaning
NILM	Negative for intraepithelial lesion or malignancy (normal)
ASC-US	Atypical squamous cells of undetermined significance
ASC-H	Atypical squamous cells, cannot exclude HSIL
LSIL	Low-grade SIL (≈ HPV effect/koilocytosis, CIN 1)
HSIL	High-grade SIL (≈ CIN 2/3)
AGC	Atypical glandular cells (endocervical/endometrial)
SCC / Adenocarcinoma	Frankly malignant cells

The Bethesda report also states specimen adequacy ("satisfactory / unsatisfactory") and presence of the TZ component.

High-yield: Koilocytes (perinuclear halo + raisinoid hyperchromatic nucleus) are the hallmark of HPV cytopathic effect and indicate LSIL.

---

7. Management of abnormal Pap results — the "next step"

The single principle: cytology screens → colposcopy + biopsy confirms → treatment is for histology-proven HSIL/CIN 2–3.

General approach flow:

Abnormal Pap → Triage (HPV test / repeat cytology / age) → Colposcopy → Directed biopsy (histology) → Treat CIN 2/3 (ablation or excision), follow CIN 1.

Pap result	Standard next step (NEET-PG answer)
ASC-US	Reflex HPV testing is preferred. HPV+ → colposcopy; HPV− → routine/repeat in 1 yr. (Alternative: repeat cytology at 6–12 months.)
ASC-US in adolescents	Conservative — repeat cytology; do not over-treat.
LSIL	Colposcopy (HPV usually positive, so reflex testing less useful).
ASC-H	Colposcopy (high risk of underlying HSIL).
HSIL	Colposcopy + biopsy, or "see-and-treat" / immediate LEEP in select adults.
AGC	Colposcopy + endocervical curettage, and endometrial sampling if ≥35 yr or abnormal bleeding (to catch glandular/endometrial pathology).

High-yield: For ASC-US, the preferred triage is reflex HPV DNA testing. For LSIL, ASC-H, and HSIL, go directly to colposcopy. For AGC, add endocervical curettage ± endometrial biopsy.

---

8. Colposcopy & biopsy

Colposcopy = magnified (×6–40) examination of the cervix after applying agents:

• 3–5% acetic acid: dysplastic, high-nuclear-density areas turn acetowhite. Abnormal vascular patterns — punctation, mosaicism, atypical vessels — point to higher-grade lesions.
• Lugol's iodine (Schiller's test): normal glycogen-rich squamous epithelium stains mahogany brown; dysplastic/columnar epithelium is glycogen-poor and stays pale/yellow = Schiller positive (abnormal). Biopsy the Schiller-positive area.

Satisfactory (adequate) colposcopy requires visualisation of the entire SCJ and the upper limit of any lesion. If the SCJ recedes into the canal (post-menopausal women) the colposcopy is "inadequate" → diagnostic excision (cone) is needed.

High-yield: Schiller's test — brown = normal (glycogen present); pale/non-staining = abnormal. Biopsy the iodine-negative, acetowhite area.

---

9. Treatment of CIN

Decided by histology, not cytology.

Ablative (destroy tissue, no specimen): cryotherapy, laser, cold coagulation. Only when colposcopy is satisfactory, lesion fully visible, ectocervical, no glandular/invasive disease, and cytology–histology agree.

Excisional (provide a specimen for margins):

• LEEP/LLETZ (Loop Electrosurgical Excision Procedure / Large Loop Excision of the TZ) — first-line, office-based, treatment of choice for CIN 2/3. Diagnostic and therapeutic.
• Cold-knife conisation (CKC): for suspected microinvasion, AIS (adenocarcinoma in situ), discrepant cytology–histology, lesion extending into canal, or unsatisfactory colposcopy. Gives clean margins (no thermal artefact).

CIN grade	Preferred management
CIN 1	Usually observe/follow up (high spontaneous regression, esp. young women). Treat only if persistent >2 yr.
CIN 2/3	Excision (LEEP) preferred; ablation acceptable if criteria met.
AIS / suspected microinvasion	Cold-knife cone (then definitive surgery as indicated).

High-yield: LEEP is the treatment of choice for CIN 2/3. Cold-knife conisation is preferred when you suspect microinvasion or adenocarcinoma in situ, or when colposcopy is unsatisfactory.

Complication of excision: cervical incompetence, cervical stenosis, and increased risk of preterm birth / mid-trimester loss in future pregnancy — a frequent exam point.

---

10. Screening guidelines & prevention

Primary prevention — HPV vaccine:

• Quadrivalent (6,11,16,18), bivalent (16,18), nonavalent (9 types).
• Ideal age 9–14 years, before sexual debut (2-dose schedule); 3 doses if ≥15 yr or immunocompromised.

Secondary prevention — screening (ACS/USPSTF style):

Age	Screening
<21 yr	No screening (even if sexually active)
21–29 yr	Cytology every 3 years
30–65 yr	HPV testing every 5 yr (preferred) OR co-test (cytology+HPV) every 5 yr OR cytology every 3 yr
>65 yr	Stop if adequate prior negative screening
After hysterectomy (for benign disease, cervix removed)	Discontinue

Low-resource (India) — "Screen-and-treat": VIA (Visual Inspection with Acetic acid) — acetowhite lesion → treat with cryotherapy/thermal ablation in the same visit. Cheap, single-visit, recommended by WHO/Govt of India for population screening. VILI uses Lugol's iodine.

High-yield: Cervical screening starts at 21 yr regardless of sexual activity. For low-resource settings, VIA + cryotherapy (single-visit "screen-and-treat") is the strategy of choice; HPV DNA testing is the WHO-preferred primary modality where feasible.

WHO 90–70–90 goal (elimination by 2030): 90% girls vaccinated by 15, 70% women screened with a high-performance test (twice by 45), 90% with disease treated.

---

11. Key differentials & "do not confuse"

• Ectropion vs early carcinoma: both red/friable — always confirm with cytology/colposcopy before labelling benign.
• Cervical polyp vs prolapsed submucous fibroid vs malignant growth — histology decides.
• CIN (histology) vs SIL (cytology) — different naming systems for the same biological continuum.
• ASC-US vs LSIL — ASC-US is "atypia of unknown significance" (triage with HPV); LSIL implies HPV effect (straight to colposcopy).
• Nabothian cyst vs malignancy — Nabothian is benign retention cyst, no treatment.

Mnemonics:

• HPV oncoproteins: "E6 eats p53, E7 wrecks Rb."
• High-risk types: "16 & 18 are the gangsters; 6 & 11 just give warts."
• Schiller: "Iodine loves glycogen — normal goes brown, disease stays pale."

---

Recently asked / exam angle

• "Most common site of cervical cancer" → transformation zone / SCJ.
• "Next step in ASC-US" → reflex HPV DNA testing (or repeat cytology); colposcopy if HPV positive.
• "Next step in LSIL/HSIL on Pap" → colposcopy with directed biopsy.
• "Treatment of choice for CIN 2/3" → LEEP (LLETZ).
• "When is cold-knife cone preferred over LEEP?" → suspected microinvasion, AIS, unsatisfactory colposcopy, positive ECC.
• "Schiller's test positive means" → iodine-negative (pale) area = abnormal.
• "Stain for Pap smear" → Papanicolaou stain; fixative → 95% ethanol.
• "Age to start screening" → 21 years.
• "HPV types in 70% of cancers" → 16 and 18.
• "Hallmark cell of HPV" → koilocyte.
• "Single-visit screen-and-treat in India" → VIA + cryotherapy.
• Image-based MCQs: koilocytes on cytology, acetowhite epithelium/mosaicism on colposcopy, Nabothian cyst, cervical polyp.

---

Rapid revision

1. Transformation zone (between old and new SCJ) is the origin of >90% of cervical cancers.
2. SCJ moves out in pregnancy/OCP (ectropion), recedes in at menopause (unsatisfactory colposcopy).
3. HPV 16 & 18 cause ~70% of cancers; 6 & 11 cause warts. E6→p53, E7→Rb.
4. Pap = cytology/Bethesda (SIL); biopsy = histology (CIN). Don't mix them.
5. Pap: no lubricant, fix in 95% ethanol, Papanicolaou stain; LBC allows reflex HPV.
6. Koilocyte = HPV hallmark = LSIL.
7. ASC-US → reflex HPV test. LSIL / ASC-H / HSIL → colposcopy + biopsy. AGC → colposcopy + ECC ± endometrial biopsy.
8. Colposcopy: acetic acid → acetowhite; Schiller's iodine — brown = normal, pale = abnormal.
9. CIN 1 → observe; CIN 2/3 → LEEP (treatment of choice); AIS/microinvasion → cold-knife cone.
10. LEEP/cone increase future risk of preterm birth and cervical stenosis/incompetence.
11. Screening starts at 21 yr; HPV testing every 5 yr is preferred at 30–65 yr; stop after 65 if prior negatives.
12. HPV vaccine best at 9–14 yr before sexual debut (2 doses); India uses VIA + cryotherapy screen-and-treat; WHO target = 90–70–90 by 2030.